⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

November 9, 2026Diabetes Obesity and MetabolismOpen Access

Continuous Glucose Monitoring in Obesity Without Diabetes: An Unnecessary Gadget or a Gateway to Precision Care?

Theocharis Koufakis Kalliopi Kotsa Carel W. le Roux

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

T.K. has received honoraria for lectures from AstraZeneca, Sanofi, Boehringer Ingelheim, Pharmaserve Lilly, ELPEN, Menarini, Roche Diagnostics and Novo Nordisk, for serving on advisory boards from Novo Nordisk, Roche Diagnostics, Sanofi and Boehringer Ingelheim and has participated in sponsored studies by Eli Lilly, AstraZeneca, Boehringer Ingelheim and Novo Nordisk.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Koufakis et al. (2026) studied this question.

synapsesocial.com/papers/6af556beb1e51a34e65a1f9f https://doi.org/10.1111/dom.71546

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

12663-P: Effects of a 12-Month Weight Management Program Integrated with Continuous Glucose Monitoring on Body Weight and Glycemic Control: A Randomized Controlled Trial in Patients with Type 2 DiabetesRCT · 2026
22923-LB: A Remote Program for Navigator- and Pharmacist-Led Implementation of Obesity MedicationsOriginal Research · 2026
3Rethinking Muscle Health Assessment in <scp>GLP</scp> ‐1–Based Therapies for Obesity: Beyond Lean MassReview · 2026 · 10 citations
42813-LB: CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 StudyRCT · 2026
5Beyond the CE Mark: A Call to Action for Minimum CGM Accuracy Standards in Central and Eastern European NationsReview · 2026
6<scp>TOS</scp> / <scp>OMA</scp> / <scp>OAC</scp> Expert Guidance Statement on Obesity Pharmacotherapy: A Humbling Call to ActionSystematic Review · 2026
71697-P: Further Real-World Outcomes Using Medication and Intensive Lifestyle Intervention to Treat Obesity and Improve Diabetes at Scale2024
82202-P: The Cardioprotective Effect of Glucagon-Like Peptide 1 Receptor Agonist in a Trial Inspired, and Wider, Population Individuals Living with Type 2 Diabetes: A Target Trial Emulation Study in CPRDRCT · 2026
9Screening for Nutritional Risk in Adults Receiving Obesity Treatment: A Systematic Literature Review of Available Tools and Identification of Conceptual GapsDiabetes Obesity and Metabolism · 2026
10Diabetic Ketoacidosis: Systematic Review and Meta‐AnalysisDiabetes Obesity and Metabolism · 2026

More from Diabetes Obesity and Metabolism

More from University College Dublin

More from Aristotle University of Thessaloniki